In recent years there have been many attempts to utilize the properties of the newer synthetic ion-exchange reagents for the separation of bases and amino-acids, but the application of truly ...

Producing novel antibody variants, including multi-specifics and even some traditional monoclonal antibodies (mAbs), can result in high levels of product-related impurities, including aggregates.

GC Biopharma USA's rigorous studies have confirmed that a novel 10% IVIG manufacturing process, including CEX chromatography, is a reliable means of removing FXIa from the final preparation. After ...